These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Serological Screening of Immunoglobulin G against SARS-CoV-2 Nucleocapsid and Spike Protein before and after Two Vaccine Doses among Healthcare Workers in Japan. Hiramoto S; Miyashita D; Kimura T; Niwa T; Uchida A; Sano M; Murata M; Nagasawa T; Tsunekawa K; Aoki T; Yoshida A; Kato T; Yanagisawa K; Tokue Y; Murakami M Tohoku J Exp Med; 2022 May; 257(1):57-64. PubMed ID: 35354694 [TBL] [Abstract][Full Text] [Related]
7. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
8. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2. Lin L; Ting S; Yufei H; Wendong L; Yubo F; Jing Z Virus Res; 2020 Oct; 288():198082. PubMed ID: 32621841 [TBL] [Abstract][Full Text] [Related]
9. Assessment of Immunogenic and Antigenic Properties of Recombinant Nucleocapsid Proteins of Five SARS-CoV-2 Variants in a Mouse Model. Rak A; Gorbunov N; Kostevich V; Sokolov A; Prokopenko P; Rudenko L; Isakova-Sivak I Viruses; 2023 Jan; 15(1):. PubMed ID: 36680269 [TBL] [Abstract][Full Text] [Related]
10. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
11. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study]. Özgür D; Tütüncü EE Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958 [TBL] [Abstract][Full Text] [Related]
12. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. Lin WS; Chen IC; Chen HC; Lee YC; Wu SC Front Immunol; 2021; 12():795741. PubMed ID: 34925381 [TBL] [Abstract][Full Text] [Related]
13. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals. Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S Front Immunol; 2022; 13():876533. PubMed ID: 35711413 [TBL] [Abstract][Full Text] [Related]
14. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455 [TBL] [Abstract][Full Text] [Related]
15. Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination? Yahi N; Chahinian H; Fantini J J Infect; 2021 Nov; 83(5):607-635. PubMed ID: 34384810 [TBL] [Abstract][Full Text] [Related]
16. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521 [TBL] [Abstract][Full Text] [Related]
17. Nucleocapsid protein of SARS-CoV-2 is a potential target for developing new generation of vaccine. Feng W; Xiang Y; Wu L; Chen Z; Li Q; Chen J; Guo Y; Xia D; Chen N; Zhang L; Zhu S; Zhao KN J Clin Lab Anal; 2022 Jun; 36(6):e24479. PubMed ID: 35527696 [TBL] [Abstract][Full Text] [Related]
18. Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting. Lim HX; Masomian M; Khalid K; Kumar AU; MacAry PA; Poh CL Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457159 [TBL] [Abstract][Full Text] [Related]
19. Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin. Pušnik J; Zorn J; Monzon-Posadas WO; Peters K; Osypchuk E; Blaschke S; Streeck H Nat Commun; 2024 Apr; 15(1):3102. PubMed ID: 38600072 [TBL] [Abstract][Full Text] [Related]
20. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]